Skip to search formSkip to main contentSkip to account menu

Xcytrin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
The FDA largely approves or disapproves drugs based on average treatment effects. Given widespread heterogeneity in treatment… 
Review
2007
Review
2007
Despite recent advances in technology, targeting, and chemotherapy, brain metastasis from non-small cell lung cancer (NSCLC… 
2006
2006
Liquid chromatography–fluorescence (LC–FLS), liquid chromatography–tandem mass spectrometry (LC–MS/MS) and inductively coupled… 
2005
2005
The biotransformation of motexafin gadolinium (MGd, Xcytrin) was investigated in subcellular rat and human liver fractions… 
2005
2005
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
2005
2005
Motexafin gadolinium (MGd, Xcytrin) is a tumor-selective redox mediator that oxidizes intracellular reducing metabolites and… 
2004
2004
3203 Background: Motexafin gadolinium (Xcytrin) is a novel therapeutic that concentrates in tumors and generates reactive oxygen… 
2004
2004
2016 Motexafin gadolinium (MGd, Xcytrin ® ) is a redox mediator that catalyzes the oxidation of intracellular reducing…